Yale University

Publications

Filters: Author is Moody, David E  [Clear All Filters]
2005
Chawarski, Marek C., David E. Moody, Juliana Pakes, Patrick G. O'Connor, and Richard S. Schottenfeld. "Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms." Journal of substance abuse treatment 29, no. 4 (2005): 307-12. Abstract
2006
McCance-Katz, Elinore F., David E. Moody, Gene D. Morse, Gerald Friedland, Patricia Pade, Jennifer Baker, Anika Alvanzo, Patrick Smith, Abayomi Ogundele, Peter Jatlow et al. "Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S224-34. Abstract
McCance-Katz, Elinore F., David E. Moody, Patrick F. Smith, Gene D. Morse, Gerald Friedland, Patricia Pade, Jennifer Baker, Anika Alvanzo, Peter Jatlow, and Petrie M. Rainey. "Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S235-46. Abstract
2007
McCance-Katz, Elinore F., David E. Moody, Gene D. Morse, Qing Ma, Robin DiFrancesco, Gerald Friedland, Patricia Pade, and Petrie M. Rainey. "Interaction between buprenorphine and atazanavir or atazanavir/ritonavir." Drug and alcohol dependence 91, no. 2-3 (2007): 269-78. Abstract
2009
Bruce, Douglas R., Frederick L. Altice, David E. Moody, Shen-Nan Lin, Wenfang B. Fang, John P. Sabo, Jan M. Wruck, Peter J. Piliero, Carolyn Conner, Laurie Andrews et al. "Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone." Drug and alcohol dependence 105, no. 3 (2009): 234-9. Abstract
2010
Bruce, Robert Douglas, Frederick L. Altice, David E. Moody, Gene D. Morse, Laurie Andrews, Shen-Nan Lin, Wenfang B. Fang, Qing Ma, and Gerald H. Friedland. "Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir." Journal of acquired immune deficiency syndromes (1999) 54, no. 5 (2010): 511-4. Abstract
2011
Bruce, Douglas R., David E. Moody, Wenfang B. Fang, Diane Chodkowski, Laurie Andrews, and Gerald H. Friedland. "Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone." The American journal of drug and alcohol abuse 37, no. 4 (2011): 224-8. Abstract
McCance-Katz, Elinore F., David E. Moody, Sudha Prathikanti, Gerald Friedland, and Petrie M. Rainey. "Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients." Drug and alcohol dependence 118, no. 2-3 (2011): 326-34. Abstract
2013
Douglas Bruce, R., David E. Moody, Diane Chodkowski, Laurie Andrews, Wenfang B. Fang, Jerdravee Morrison, Theresa L. Parsons, and Gerald H. Friedland. "Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment." The American journal of drug and alcohol abuse 39, no. 2 (2013): 80-5. Abstract
Bruce, Douglas R., David E. Moody, Frederick L. Altice, Marc N. Gourevitch, and Gerald H. Friedland. "A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice." Expert review of clinical pharmacology 6, no. 3 (2013): 249-69. Abstract
2014
Tetrault, Jeanette M., Elinore F. McCance-Katz, David E. Moody, David A. Fiellin, Bonnie S. Lruie, An T. Dinh, and Lynn E. Fiellin. "The impact of recent cocaine use on plasma levels of methadone and buprenorphine in patients with and without HIV-infection." Journal of substance abuse treatment (2014). Abstract